Manchester University NHS Foundation Trust

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	16/ES/0001	193859	A Phase 3, randomized, double-blind, placebo-controlled, multicentre study to investigate the efficacy and safety of Mongersen (GED-0301) for the treatment of subjects with active Crohn's Disease	Number Agreed	3	3	Date Agreed	31/03/2017	2	20/10/2017	2	Withdrawn By Sponsor
2	16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN?S DISEASE	Range Agreed	1	3	Date Agreed	30/11/2017	1	20/10/2017	1	Withdrawn By Sponsor
3	17/SC/0236	226436	PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY	Range Agreed	1	6	Date Agreed	31/12/2017	6	27/11/2017	6	Recruitment Finished
4	16/SC/0542	208245	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITYOF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULARDEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY	Range Agreed	1	4	Date Agreed	31/03/2018	2	20/11/2017	2	Recruitment Finished
5	16/ES/0001A	193859	Revolve (Celgene GED-0301-CD-002)	Number Agreed	3	3	Date Agreed	29/11/2017	0	19/10/2017	0	Withdrawn By Sponsor
6	17/NW/0019	212375	A3921192 SOAR ? A Study of a Once-A-day investigational drug for RA	Number Agreed	2	2	Date Agreed	21/03/2019	0	31/10/2017	0	Withdrawn By Sponsor
7	13/WM/0235	126333	ATrial FibrillaTion ProgrESsion Trial	Number Agreed	1	1	Date Agreed	01/08/2017	0	27/02/2018	5	Withdrawn By Sponsor
8	13/LO/0867	126972	Double-blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monother	Number Agreed	4	4	Date Agreed	30/03/2018	15	05/01/2018	15	Recruitment Finished
9	15/NW/0698	183781	A twenty six week, randomized, openlabel, 2 arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo? compared to standard of care insulin, in basal insulin treated patients with uncontr	Number Agreed	4	4	Date Agreed	07/10/2016	0	20/12/2017	0	Recruitment Finished
10	17/SC/0016	218645	A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable PleuralMesothelioma	Range Agreed	4	6	Date Agreed	30/06/2018	3	22/02/2018	3	Recruitment Finished
11	14/NI/1038	153733	A Prospective Randomized Controlled Study Evaluating the Safety and Efficacy of EVICEL? used for Suture-Line Sealing in Dura-Mater Closure during Paediatric Neurosurgical Cranial Procedures	Range Agreed	1	6	Date Agreed	01/05/2019	2	05/01/2018	2	Recruitment Finished

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
12	15/LO/1289	181953	An international, multicenter, randomized, double-blind, placebo-controlledphase 3 trial investigating the efficacy andsafety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheralartery disease	Number Agreed	4	4	Date Agreed	04/09/2017	9	08/12/2017	13	Recruitment Finished
13	15/NW/0827	181796	A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients withRelapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation	Number Agreed	4	4	Date Agreed	28/02/2017	0	20/02/2018	0	Recruitment Finished
14	16/LO/0361	193839	Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults	Number Agreed	4	4	Date Agreed	08/12/2016	7	27/11/2017	7	Recruitment Finished
15	17/NW/0145	217442	Longitudinal study of chronic wounds using novel wound measurement technologies	Range Agreed	10	15	Date Agreed	01/05/2018	16	31/01/2018	16	Recruitment Finished
16	17/NE/0136	224520	A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B	Number Agreed	1	1	Date Agreed	31/10/2017	1	18/10/2017	1	Recruitment Finished
17	16/WM/0170	195010	ISIS 304801-CS7 -An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)	Range Agreed	1	2	Date Agreed	31/12/2017	5	31/12/2017	5	Recruitment Finished
18	17/EM/0044	217658	A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks inpatients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).	Number Agreed	2	2	Date Agreed	31/05/2018	0	21/02/2018	0	Recruitment Finished
19	14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	50	50	Date Agreed	03/09/2018	116	03/05/2018	116	Recruitment Finished
20	17/SC/0242	222650	A Phase 2A, Randomized, Double-Blind, Placebo- Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction	Number Agreed	4	4	Date Agreed	30/06/2018	2	29/06/2018	2	Recruitment Finished
21	18/YH/0167	246108	A Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered combination of GLPG3067, GLPG2222 and GLPG2737, in adult subjects with cystic fibr	Number Agreed	1	1	Date Agreed	31/12/2050	0	28/06/2018	0	Withdrawn By Sponsor
22	16/LO/0803	204170	Study of MiniMed? 640G Insulin Pump with SmartGuard? in prevention of Low Glucose Events in adults with Type 1diabetes	Range Agreed	5	7	Date Agreed	30/09/2017	6	03/04/2018	6	Recruitment Finished
23	16/EM/0436	213166	Single arm study of ALXN1210 in complement inhibitor treatment-naive adult and adolescent patients with atypical hemolytic uremic syndrome (aHUS)	Range Agreed	1	1	Date Agreed	28/02/2018	0	01/06/2018	0	Recruitment Finished

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
24	17/EE/0026	220207	A Prospective, Randomized, Controlled, Multi-Center Clinical Study of theACRYSOF IQ Extended Depth of Focus (EDF)	Number Agreed	12	12	Date Agreed	30/03/2018	9	06/04/2018	9	Recruitment Finished
25	16/WM/0512	218042	A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ferric Maltol at Three Dosage Levels in Paediatric Subjects aged 10-17 years of age with iron deficiency (with or withou	Range Agreed	3	4	Date Agreed	31/10/2017	2	15/03/2018	4	Recruitment Finished
26	17/LO/1502	232726	An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS443139 in Huntington?s Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139	Range Agreed	1	4	Date Agreed	31/05/2019	4	24/04/2018	4	Recruitment Finished
27	17/SC/0122	224090	AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS)	Range Agreed	4	8	Date Agreed	28/02/2018	8	28/02/2018	8	Recruitment Finished
28	17/LO/0794	223700	A 52-Week Multicenter, Randoimized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis who are Biologic Disease-Modifying Anti-Rheumatic Drug Naive	Number Agreed	2	2	Date Agreed	13/05/2019	1	18/05/2018	1	Recruitment Finished
29	16/LO/1211	207428	A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics,Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera? in Anti TNFInadequate Responder Patients with Moderate to Severe RA	Range Agreed	1	2	Date Agreed	01/08/2018	0	20/07/2018	0	Recruitment Finished
30	18/NW/0412	247770	To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a low calorie peptide based paediatric tube-feed formula for children over 1 year of age	Range Agreed	1	7	Date Agreed	31/08/2018	5	31/08/2018	5	Recruitment Finished
31	13/NW/0003	117310	AKPA 3-001: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Severe Sepsis and Coagulopathy	Range Agreed	1	6	Date Agreed	30/09/2018	3	13/09/2018	3	Recruitment Finished
32	13/NI/0123	135437	MILES - UK: Post marketing, multicenter, single arm, obervational clinical registry to evaluate safety and efficacy of BioMime sirolimus eluting stent system in all comers real world population with coronary artery stenosis in United Kingdom	Number Agreed	10	10	Date Agreed	31/07/2018	25	31/08/2018	25	Recruitment Finished

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
33	15/WS/0061	178522	A Randomized, Doubleblind, Eventdriven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and SignificantCoronary Artery Disease Fo	Number Agreed	5	5	Date Agreed	15/10/2017	1	16/10/2017	1	Recruitment Finished
34	15/LO/1079	177212	A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem? Therapy in Subjects with Acute RespiratoryDistress Syndrome	Range Agreed	2	3	Date Agreed	31/03/2018	2	19/09/2018	4	Recruitment Finished
35	16/SC/0039	188354	A Phase 2, Multicenter, Randomized, Double-Blind, Parallel,Placebo-Controlled Study of LY3074828 in Subjects withModerate to Severe Ulcerative Colitis	Range Agreed	2	5	Date Agreed	31/05/2017	0	03/10/2017	0	Recruitment Finished
36	17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studyto Evaluate the Safety and Efficacy of CCX168 (Avacopan) inPatients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab orCyclophosphamide/	Number Agreed	2	2	Date Agreed	31/12/2018	2	04/07/2018	2	Recruitment Finished
37	17/YH/0083	220358	A Randomized Controlled Trial of Gentle Touch/Early Massage with a New Wash and Lotion Regimen for Improved Skin Barrier Strength, Parental Bonding, and Physical Development in Newborn Babies	Number Agreed	30	30	Date Agreed	30/09/2017	32	14/11/2017	38	Recruitment Finished
38	17/EM/0405	223871	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis	Range Agreed	1	10	Date Agreed	30/09/2018	3	21/09/2018	3	Recruitment Finished
39	16/EM/0037	196490	LY vs. Placebo with Active Control I1F-MC-RHBW: AS TNF-Experienced Phase III	Number Agreed	4	4	Date Agreed	31/01/2018	3	20/12/2017	3	Recruitment Finished
40	16/NW/0089	165834	IronWood	Number Agreed	40	40	Date Agreed	30/04/2017	18	01/08/2018	42	Recruitment Finished
41	17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study toEvaluate the Safety and Efficacy of VX-659 CombinationTherapy in Subjects Aged 18 Years and Older With CysticFibrosis	Number Agreed	4	4	Date Agreed	28/02/2018	1	02/04/2018	1	Recruitment Finished
42	18/NE/0103	241640	A Phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659 combination therapy in subjects with cystic fibrosis who are homozygous for the F508del Mutation (F/F)	Range Agreed	1	2	Date Agreed	31/01/2018	0	21/07/2018	2	Recruitment Finished